206 related articles for article (PubMed ID: 20169072)
1. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.
Khankin EV; Mutter WP; Tamez H; Yuan HT; Karumanchi SA; Thadhani R
PLoS One; 2010 Feb; 5(2):e9246. PubMed ID: 20169072
[TBL] [Abstract][Full Text] [Related]
2. Detection and quantification of the soluble form of the human erythropoietin receptor (sEpoR) in the growth medium of tumor cell lines and in the plasma of blood samples.
Westphal G; Braun K; Debus J
Clin Exp Med; 2002 May; 2(1):45-52. PubMed ID: 12049189
[TBL] [Abstract][Full Text] [Related]
3. [Possible role of soluble erythropoietin receptors in renal anemia].
Sakaguchi M; Maeda Y; Naiki Y; Hasegawa H; Kanamaru A
Nihon Jinzo Gakkai Shi; 2002 Oct; 44(7):524-9. PubMed ID: 12476588
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction.
Okonko DO; Marley SB; Anker SD; Poole-Wilson PA; Gordon MY
Int J Cardiol; 2013 Apr; 164(3):359-64. PubMed ID: 21821297
[TBL] [Abstract][Full Text] [Related]
5. Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors.
Inrig JK; Bryskin SK; Patel UD; Arcasoy M; Szczech LA
BMC Nephrol; 2011 Dec; 12():67. PubMed ID: 22152013
[TBL] [Abstract][Full Text] [Related]
6. Plasma soluble erythropoietin receptor is decreased during sleep in Andean highlanders with Chronic Mountain Sickness.
Villafuerte FC; Corante N; Anza-Ramírez C; Figueroa-Mujíca R; Vizcardo-Galindo G; Mercado A; Macarlupú JL; León-Velarde F
J Appl Physiol (1985); 2016 Jul; 121(1):53-8. PubMed ID: 27125843
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin pretreatment ameliorates renal ischaemia-reperfusion injury by activating PI3K/Akt signalling.
Zhang J; Zou YR; Zhong X; Deng HD; Pu L; Peng K; Wang L
Nephrology (Carlton); 2015 Apr; 20(4):266-72. PubMed ID: 25581532
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells.
Feldman L; Wang Y; Rhim JS; Bhattacharya N; Loda M; Sytkowski AJ
Prostate; 2006 Feb; 66(2):135-45. PubMed ID: 16161153
[TBL] [Abstract][Full Text] [Related]
9. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.
Arcasoy MO; Karayal AF
Biochim Biophys Acta; 2005 Apr; 1740(1):17-28. PubMed ID: 15878737
[TBL] [Abstract][Full Text] [Related]
11. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.
Arcasoy MO; Harris KW; Forget BG
Exp Hematol; 1999 Jan; 27(1):63-74. PubMed ID: 9923445
[TBL] [Abstract][Full Text] [Related]
12. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
Hamadmad SN; Hohl RJ
Biochem Pharmacol; 2007 Aug; 74(4):590-600. PubMed ID: 17586475
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin induces miRNA-210 by JAK2/STAT5 signaling in PBMCs of End-stage Renal Disease patients.
Felaco P; Felaco M; Franceschelli S; Ferrone A; Gatta DMP; Speranza L; Patruno A; De Lutiis MA; Ballerini P; Sirolli V; Grilli A; Bonomini M; Pesce M
FEBS J; 2020 Dec; 287(23):5167-5182. PubMed ID: 32196922
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin acts as an anti-inflammatory signal on murine mast cells.
Wiedenmann T; Ehrhardt S; Cerny D; Hildebrand D; Klein S; Heeg K; Kubatzky KF
Mol Immunol; 2015 May; 65(1):68-76. PubMed ID: 25645506
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes.
Zhang J; Wu Y; Jin Y; Ji F; Sinclair SH; Luo Y; Xu G; Lu L; Dai W; Yanoff M; Li W; Xu GT
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):732-42. PubMed ID: 18235022
[TBL] [Abstract][Full Text] [Related]
16. The erythropoietin receptor is not required for the development, function, and aging of rods and cells in the retinal periphery.
Caprara C; Britschgi C; Samardzija M; Grimm C
Mol Vis; 2014; 20():307-24. PubMed ID: 24644405
[TBL] [Abstract][Full Text] [Related]
17. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation.
Malyszko J; Malyszko JS; Mysliwiec M
Ren Fail; 2009; 31(7):544-8. PubMed ID: 19839848
[TBL] [Abstract][Full Text] [Related]
18. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.
Kalim S; Tamez H; Wenger J; Ankers E; Trottier CA; Deferio JJ; Berg AH; Karumanchi SA; Thadhani RI
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1927-34. PubMed ID: 23970130
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3.
Chin H; Wakao H; Miyajima A; Kamiyama R; Miyasaka N; Miura O
Blood; 1997 Jun; 89(12):4327-36. PubMed ID: 9192755
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes.
Pan Y; Shu JL; Gu HF; Zhou DC; Liu XL; Qiao QY; Fu SK; Gao FH; Jin HM
Mol Cell Endocrinol; 2013 Mar; 367(1-2):116-23. PubMed ID: 23313788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
